AP NEWS

Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2018-2024 - A US$ 140 Billion Opportunity - ResearchAndMarkets.com

November 20, 2018

DUBLIN--(BUSINESS WIRE)--Nov 20, 2018--The “Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024” clinical trials has been added to ResearchAndMarkets.com’s offering.

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period.

Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024 Report Highlights:

Significance for Monoclonal Antibodies for Cancer Treatment Global Cancer Monoclonal Antibodies Market Overview Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication Global Cancer Monoclonal Antibodies Pipeline: 697 mAb Marketed Cancer Monoclonal Antibodies: 60 Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion

The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together.

Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient’s lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies.

Key Topics Covered:

1. Introduction to Monoclonal Antibodies

2. Monoclonal Antibodies Classification

3. Monoclonal Antibodies Mechanisms

4. Significance for Monoclonal Antibodies for Cancer Treatment

5. Global Cancer Monoclonal Antibodies Market Overview

6. Global Cancer Monoclonal Antibodies Market Future Outlook

7. Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight

9. Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight

11. Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight

15. Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight

17. Global - Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

18. Global - Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase

19. Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

20. Global - Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

21. Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

22. Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight

24. Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical

26. Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight

28. Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

29. Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight

31. Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

32. Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight

34. Competitive Landscape

Abbvie Amgen Bayer HealthCare Biogen Idec Eli Lilly Genmab Gilead Sciences GlaxoSmithKline Novartis Pfizer Roche Seattle Genetics

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/tkqkcd/global_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005335/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Clinical Trials,Biopharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/20/2018 07:34 AM/DISC: 11/20/2018 07:34 AM

http://www.businesswire.com/news/home/20181120005335/en

AP RADIO
Update hourly